Standard oral hypoglycemic agents tend to manage hyperglycemia and other diabetic complications through various mechanisms, i.e., decreasing insulin resistance by acting on peroxisome proliferator-activated receptors (PPARs), making insulin more effective or releasing bound insulin, reducing hepatic gluconeogenesis and degradation of endogenous insulin (34, 35). This evidence concerns the gene INS and Hyperglycemia.